UNSPSC 51332002: Lintopride

This classification denotes a serotonin antagonist and antiemetic agent, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier C2R0GEU722. European Medicines Agency schedules Lintopride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08526MIG. Lintopride generally arises in the molecular formula C14H19CLN4O2.

UNSPSC 51332002 Lintopride is a Commodity code that encompasses pharmaceutical products and drug-related medical supplies procured by state and local health agencies, though recent state and local solicitations tagged under this code reflect a broader scope than the nominal code name alone suggests. State and local governments are acquiring naloxone and drug deactivation systems, generic multi-source pharmaceuticals, and over-the-counter products through formal competitive bidding and cooperative purchasing vehicles. Issuing bodies include county health departments, state health and human services commissions, and multistate cooperative purchasing alliances administering contracts on behalf of member jurisdictions. The work involves sourcing finished pharmaceutical products and medical devices through authorized wholesalers, managing inventory fulfillment on quarterly or ongoing schedules, and ensuring compliance with FDA manufacturing practices, Drug Supply Chain Security Act requirements, and federal regulations when federal funding is involved.

Recent activity spans Florida, Texas, and Minnesota. Seminole County, Florida issued IFB 60459723LAS (due July 26, 2023) for procurement of 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries to the county community health building, requiring bidders to include shipping and delivery costs and comply with E-Verify and drug-free workplace certification. The Texas Health and Human Services Commission posted RFI HHS0017013 in April 2026 to solicit vendor capabilities for a Therapeutic Pharmacy Initiative Direct-to-Manufacturer Prescriptions program, seeking information on direct contracting models with pharmaceutical manufacturers outside traditional pharmacy benefit managers and group purchasing organizations. The Minnesota Multistate Cooperative Purchasing Alliance issued RFP S1070000015802 (due March 26, 2026) to establish multiple contracts for generic multi-source pharmaceuticals and OTC products distributed through three authorized wholesalers (AmerisourceBergen Drug Corporation, Cardinal Health, and Morris & Dickson Co., LLC) across participating state and local facilities including Oregon, with pricing weighted 75 percent and compliance and administrative requirements at 25 percent.